Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine

Pediatrics International

Volumn 45, Issue 3, 2003, Pages 314-318

  Kanra, Güler ^a   Viviani, Simonetta ^b   Yurdakök, Kadriye ^a   Özmert, Elif ^a   Anemona, Alessandra ^b   Yalçin, Songül ^a   Demiralp, Okan ^c   Bilgili, Nihan ^c   Kara, Ates ^a   Cengiz, Ali Bülent ^a   Mutlu, Belgin ^d   Baldini, Alexandra ^b   Marchetti, Elisa ^b   Podda, Audino ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Chiron Vaccines   (Italy)

^c Gülveren Child Center   (Turkey)

^d Chiron Vaccines   (Turkey)

Author keywords

Adjuvants; Aluminum hydroxide; Haemophilus influenzae type b; Vaccine

Indexed keywords

ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HIB AIPO; IMMUNOLOGICAL ADJUVANT; ORAL POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VAXEMHIB;

ANTIBODY TITER; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INJECTION PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOMNOLENCE; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ALUMINUM HYDROXIDE; ANTIBODY FORMATION; BACTERIAL PROTEINS; DOUBLE-BLIND METHOD; HAEMOPHILUS VACCINES; HUMANS; IMMUNOGLOBULIN G; INFANT; PHOSPHATES; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 0041662149     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01706.x     Document Type: Article

References (16)

1. Peltola H, Aavitsland P, Hansen KG, Jònsdòttir KE, Nøkbley H, Romanus V. Perspective: A five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J. Infect. Dis. 1999; 179: 223-9.
2. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev. 2000; 13: 302-17.
3. Centers for Disease Control and Prevention (USA). Progress toward eliminating Haemophilus influenzae type b disease among infants and children in the United States, 1987-1997. MMWR 1998; 47: 993-9.
4. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Haemophilus influenzae type b bacteremia infections with the capsular polysaccharide vaccine. N. Engl. J. Med. 1984; 310: 1561-6.
5. Vella PP, Staub JM, Armstrong J et al. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine. Pediatrics 1990; 85: 668-75.
6. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J. 1998; 17: 117-22.
7. Käyhty H, Mäkalä PH, Peltola H. Immunological basis for PRP vaccines. In: Ellis RW, Granoff DM (eds). Development and Clinical Uses of Haemophilus B Conjugate Vaccines. Marcel Dekker, New York, 1994; 1-18.
8. Costantino P, Viti S, Rappuoli R, Podda A. Semisynthetic vaccines against bacterial meningitis. Chimica Oggi 1991; 21: 13-15.
9. Galli MG, Podda A, Costantino P, Viti A, Aiello L, Ceratti F, Consonni M. Esperienza di vaccinazione anti-Haemophilus influenzae tipo b in bambini di età inferiore ai due anni. Ann. Ig. 1993; 5: 91-5.
10. Costantino P, Norelli F, Giannozzi A et al. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine 1999; 17: 1251-63.
11. Sturgess AW, Rush K, Charbonneau RJ et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminium hydroxide. Vaccine 1999; 17: 1169-78.
12. Kanra G, Viviani S, Yurdakok K et al. Safety, tolerability and immunogenicity of a Haemophilus influenzae type b vaccine containing aluminium phosphate adjuvant administered at 2, 3 and 4 months of age. Turk. J. Pediatrics 1999; 42: 421-7.
13. Mariani M, Luzzi E, Proietti D et al. A competitive enzyme-linked immunosorbent assay for measuring the levels of serum antibody to Haemophilus influenzae type b. Clin. Diagn. Lab. Immunol. 1988; 5: 667-74.
14. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 1983; 147: 1100.
15. Centers for Disease Control and Prevention (USA). Recommended Childhood Immunization Schedule, United States. MMWR 2000; 49: 35-9.
16. Wenger JD, Booy R, Heath PT, Moxon R. Chapter 35: Conjugate vaccines against Hib invasive disease. In: Levin MM, Woodrow GC, Kaper JB (eds). New Generation Vaccines, 2nd edn. Dekker, New York, 1997; 489-502.